Amgen Blew It…For Medicines Co., Esperion Too

Amgen ( AMGN ) isn’t the only drug maker g etting crushed by the data released today from its much awaited outcome study for the cholesterol-lowering drug Repatha. While Amgen shares fell almost 7%, other drug makers with cholesterol-lowering therapies in development got dragged along for the ride. Esperion Therapeutics ( ESPR ) and Medicines Company ( MDCO ) were down 22% and 14%, respectively. But Medicines Co.’s management remains underrated regarding the future of its experimental drug inclisiran, arguing that Amgen’s Fourier study was badly designed.